However, our earlier work [10] suggests that transfection and significant over-expression of ATIP1 has the ability to slow prostate cancer cell growth rate and the identification of ATIP/AT2-receptors in both normal and malignant prostatic biopsies, as shown in the present studies, indicate that this may be a potential therapeutic pathway for, not only, prostate cancer, but other prostatic diseases characterized by excessive cell growth. Here, MTUS1 is linked to prostate carcinoma.